Monday, September 11, 2017

All Research Moved To Bio5C

Thanks for visiting BioNap, Inc!

All biopharma equity research has been moved to Bio5C is 100% independent biopharma equity research based on my proprietary 5C's of Biotech™ model. The current coverage universe at Bio5C consists of several dozen mid-cap biopharma companies. My criteria include a market capitalization in excess of $100 million and a stock price greater than $5 per share.

At Bio5C, subscribers get the following services for their monthly subscription:

1) 5C Model scores on dozens of biopharma names, including individual component scores: Cash, Catalyst, Charisma, Capital Structure, and Credibility.

2) Daily Notes based on recent news or pending events.

3) Full valuation models on selection Bio5C names in the coverage universe.

4) An Active message board where subscribers can interact with Bio5C and other members.

If you're visiting this website, chances are you've read and appreciated my work in the past. At Bio5C, you get the same quality work from BioNap you've come to expect, with a far more personalized approach and 100% independent thinking. I could use your support, so please visit and continue reading my work under this new subscription-based model.

Learn more here >>

If you are an individual or professional investor looking for a custom research report...


If you are a biopharma company looking for strategic consulting services, including market research, white papers, or transaction support...

Please email me at

Friday, June 30, 2017

Initial Look At Bio5C Performance

I was saving this analysis for June, but since a few of you guys have asked me for metrics on Bio5C performance, I'll share what I have as of today. I started to score biopharma companies for Bio5C in February 2017. The service has come a long way since then. Back in February, all I had was one tab in excel with the 5C score. Now, subscribers get an excel file updated daily that has 6 tabs and research reports on two dozen names. Luckily, I saved the Bio5 score for all the names in the model on March 1st. I've added a handful of stocks since March 1st, and those are now included in the model as well.

The results are excellent - better than I expected actually! I graphed the Bio5C score on the X-axis vs. the 3-month stock return on the Y-axis and got a pretty decent R-squared score of 0.55. However, importantly, the trend line looks fantastic and the stratified data look outstanding!

Monday, April 24, 2017

New Biotech Research Service - Bio5C

I've been a stock analyst since 1999. I've focused solely on biopharma names since 2003. I've seen a lot of success and a lot of failures. It's amazing to me how many small biopharma companies continue to make the same mistakes, over, and over again. I've researched drugs with novel mechanisms of action that look outstanding in preclinical studies, only to see them fail once they hit the clinic. I've also witnessed repurposed agents that bafflingly succeed in new indications where the market wagered little hope. I've seen good drugs fail because of bad business models and terrible management and bad drugs succeed because of good business models and brilliant management. There is no true formula for success, but there are a number of roadblocks and red flags.